Specific Phobia Clinical Trial
Official title:
Optimizing Exposure in the Treatment of Anxiety in Youth: Facing Fears in Big or Smalls Steps?
Verified date | May 2021 |
Source | University of Groningen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Anxiety problems are a major concern of youth mental health given that the prevalence of anxiety disorders in Dutch adolescents aged 12 to 18 is approximately 10 percent. In this group, specific phobias are among the most common. Cognitive Behavioral Therapy (CBT) with exposure as its key ingredient, takes a prominent place in national guidelines for the treatment of anxiety disorders. These guidelines are based on empirical support that exposure is effective in the treatment of specific phobia. Therapists help phobic adolescents to overcome their fear by gradually, step by step, working their way up from less scary situations to situations that cause a greater deal of anxiety. Although it is clear that exposure is effective, the size of the steps to be taken in this process remains unclear. However, there are multiple reasons to assume that one or the other works best. On the one hand, adolescents will soon gain trust in their own abilities when taking small steps, which enlarges their feeling of self-control (e.g., self-efficacy). On the other hand there is the risk that these small steps might be experienced as safety behavior and avoidance, which is counterproductive to the essence of exposure (i.e., overcoming the fear) and undermines the potential effect. This might result in either a longer treatment or insufficient treatment benefits. Considering this risk, and the fact that confrontation with a feared object or situation in daily life is also not a step-by-step process, this study proposes to evaluate the optimal dosage of exposure, by studying whether exposure in big steps is more effective than exposure in small steps.
Status | Completed |
Enrollment | 50 |
Est. completion date | March 4, 2021 |
Est. primary completion date | March 4, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 17 Years |
Eligibility | Inclusion Criteria: - Aged between 12-17 years old and in secondary school - Sufficient knowledge of the Dutch language - Meeting the criteria of specific phobia of the situational or animal subtype Exclusion Criteria: - Absence of permission of legal guardian(s) - Currently in treatment or receiving medication for anxiety - Received CBT for anxiety in the past 12 months - Specific phobia that do not fall under the situational or animal subtype, for example: - Aerophobia: fear of flying - Emetophobia: fear of vomiting - Hemophobia: fear of blood - Hosophobia: fear of infection - Astraphobia: fear of lightning - Different and more urgent request for help - (Risk of) suicidality, psychosis or domestic violence |
Country | Name | City | State |
---|---|---|---|
Netherlands | Accare Drachten | Drachten | Friesland |
Netherlands | Accare Universitair Centrum voor Kinder en Jeugdpsychiatrie | Groningen | |
Netherlands | Accare Leeuwarden | Leeuwarden | Friesland |
Lead Sponsor | Collaborator |
---|---|
University of Groningen | ZonMw: The Netherlands Organisation for Health Research and Development |
Netherlands,
Brady EU, Kendall PC. Comorbidity of anxiety and depression in children and adolescents. Psychol Bull. 1992 Mar;111(2):244-55. Review. — View Citation
Chorpita BF, Moffitt CE, Gray J. Psychometric properties of the Revised Child Anxiety and Depression Scale in a clinical sample. Behav Res Ther. 2005 Mar;43(3):309-22. — View Citation
Craske MG, Treanor M, Conway CC, Zbozinek T, Vervliet B. Maximizing exposure therapy: an inhibitory learning approach. Behav Res Ther. 2014 Jul;58:10-23. doi: 10.1016/j.brat.2014.04.006. Epub 2014 May 9. — View Citation
EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208. — View Citation
Hedtke KA, Kendall PC, Tiwari S. Safety-seeking and coping behavior during exposure tasks with anxious youth. J Clin Child Adolesc Psychol. 2009 Jan;38(1):1-15. doi: 10.1080/15374410802581055. — View Citation
Koopmanschap MA. PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies. Expert Rev Pharmacoecon Outcomes Res. 2005 Feb;5(1):23-8. doi: 10.1586/14737167.5.1.23. — View Citation
Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther. 1979;17(3):263-7. — View Citation
Silverman WK, Saavedra LM, Pina AA. Test-retest reliability of anxiety symptoms and diagnoses with the Anxiety Disorders Interview Schedule for DSM-IV: child and parent versions. J Am Acad Child Adolesc Psychiatry. 2001 Aug;40(8):937-44. — View Citation
Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ. Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev. 2008 Jul;28(6):1021-37. doi: 10.1016/j.cpr.2008.02.007. Epub 2008 Mar 7. — View Citation
Wood JJ, Piacentini JC, Bergman RL, McCracken J, Barrios V. Concurrent validity of the anxiety disorders section of the Anxiety Disorders Interview Schedule for DSM-IV: child and parent versions. J Clin Child Adolesc Psychol. 2002 Sep;31(3):335-42. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cost-effectiveness (Healthcare costs and In quality adjusted life years) | In addition, cost-effectiveness of the intervention will be assessed by measuring costs and quality of life (effectiveness). Measuring cost-effectiveness is not the primary goal of this research but since this study is part of a larger national project in which cost-effectiveness will also be taken into account, we consider it relevant to state here.
Healthcare costs will be measured by registration of costs in a cost diary based on the Trimbos Institute and Institute of Medical Technology Assessment Questionnaire on Costs Associated with Psychiatric Illness (TiC-P) and PRODISQ. The EuroQol Questionaire (EQ-5D-Y youth version) will be used to establish quality of life as expressed in quality adjusted life years (QALYs). Healthcare costs and in quality adjusted life years are combined to report cost-effectiveness. |
Time Frame: At pre-intervention assessment (T1) and eight weeks later at follow-up assessment (T6) | |
Other | Change in specific phobia diagnosis (Interference, number of symptoms and general impression of the psychologist) | Specific phobia diagnosis will be assessed with the ADIS IV (see above). All items offer three possible answers: 'yes', 'no' or 'other' on a nominal scale (which is chosen when the adolescent answers 'I don't know' or 'sometimes'). If the adolescent meets all four criteria for specific phobia as set in the ADIS-IV, he or she can participate in the study. | Time Frame: At intake (T0), four weeks later at pre-intervention assessment (T1), another four weeks later at post-intervention assessment (T5) and another four weeks later at follow-up assessment (T6) | |
Other | Comorbid anxiety and depression symptoms | Given the high comorbidity of anxiety and depression in children, comorbid anxiety and depression will be assessed with the Revised Child Anxiety and Depression Scale for Children and Parents (RCADSC/ P) consisting of 47 items and the Phobia section of the Spence Children's Anxiety Scale for Children and Parents (SCAS-C/P) consisting of 9 items. All items are rated on a 4-point interval scale from 'never' to 'always'. Both the RCADS (Chorpita, Moffitt, & Gray, 2005) and the SCAS (Whiteside & Brown, 2008) have good psychometric properties, and are combined into the RCADSCAS for this study. | Time Frame: At pre-intervention assessment (T1), four weeks later at post-intervention assessment (T5) and another four weeks later at follow-up assessment (T6) | |
Other | Change in in-session fear before and after each exposure exercise | In-session fear is measured before and after every in-session exposure step, by asking the adolescent to provide "subjective unit of disturbance scale" (SUDS) ratings on a ratio scale 0-100 immediately before and after a new step in encountering the phobic object or situation. | During the second (T3) and the third (T4) treatment session | |
Other | In-session harm expectancy before and after each exposure exercise | In-session harm expectancy is measured before and after every in-session exposure step. Before every exposure step the adolescent is asked: a) 'What are you most worried will happen?', b) 'On a (ratio) scale 0-100, how likely does this seem?, and c) 'On a (ratio) scale 0-100, how bad would it be if the thing you are most worried about will occur?'. After every exposure step the adolescent is reminded of their worry and asked: a) 'On a (ratio) scale 0-100, how likely does it seem this would happen if we would repeat this step?', and b) 'On a (ratio) scale 0-100, how bad would it be if the thing you are most worried about will occur?'. | During the second (T3) and the third (T4) treatment session | |
Other | Change in treatment credibility and expectancy of the treatment | Credibility and expectancy of the treatment are measured by the Credibility and Expectancy Questionnaire (CEQ-C/P). This questionnaire contains 6 items all rated on a 9-point interval scale. The psychometric properties of the scale have been qualified as good. | At pre-intervention assessment (T1), four weeks later at post-intervention assessment (T5) and another four weeks later at follow-up assessment (T6) | |
Other | Change in treatment satisfaction during and after treatment | Treatment satisfaction will be measured with the Service Satisfaction Scale (SSS). Four items are rated on a 4-point interval scale ranging from 'no, definitely not' to 'yes, definitely'. The psychometric properties of the scale have been qualified as good. | At pre-intervention assessment (T1), four weeks later at post-intervention assessment (T5) and another four weeks later at follow-up assessment (T6) | |
Other | Therapeutic alliance during the treatment | Therapeutic alliance is measured by the Therapeutic Alliance Scale for Children and Parents (TAS-C/P). Both parts consist of 12 items rated on a 4-point interval scale. The psychometric properties of the scale have been qualified as good. | One week after the last intervention week, at post-intervention assessment (T5) | |
Primary | Change in specific phobia severity (Interference, number of symptoms and general impression of the psychologist) | Specific phobia severity in children will be measured with a clinical semi-structured interview using the Anxiety Disorder Interview Schedule for Children and Parents (ADIS-IV-C/P). The study will only include the section of specific phobia. Severity of the specific phobia will be rated on a 0-8 interval scale by an independent psychologist on the ADIS-IV (see above). This rating is based on the level of interference, number of symptoms and general impression of the psychologist. A rating 0, 1, 2 or 3 is labelled as no specific phobia, a rating of 4 or 5 is labelled as a mild specific phobia, whereas a rating of 6, 7 or 8 means the specific phobia is labelled as severe. This rating is used to randomize the participants to the different conditions. The ADIS-IV has good test-retest reliability and concurrent validity. | Time Frame: At intake (T0), four weeks later at pre-intervention assessment (T1), another four weeks later at post-intervention assessment (T5) and another four weeks later at follow-up assessment (T6) | |
Secondary | Change in level of anxiety (Subjective level of fear, Fearful cognitions, Bodily tension, Avoidance and Coping) | Level of anxiety compromised of Subjective level of fear, Fearful cognitions, Bodily tension, Avoidance and Coping will be measured by Visual Analogue Scales (VAS) ranging from 0-100 (ratio scale) on which the child rates the following aspects of the goal situation as set in the PE session:
Subjective level of fear: 'Not frightened at all' (0) - 'Completely frightened' (100) Fearful cognitions: 'I do not believe this at all' (0) - 'I completely believe this' (100), in which the credibility of the cognition about the feared object or situation as set in the PE session is rated. Bodily tension: 'My body feels not tense at all' (0) - 'My body feels completely tense' (100) Avoidance: 'I would never avoid this situation/object if I could' (0) - 'I would always avoid this situation/object if I could' (100) Coping: 'I cannot cope with this situation/object at all when I encounter it' (0) - 'I can completely cope with this situation/object when I encounter it' (100) |
Time Frame: In the first treatment session (T2), one week later in the second treatment session (T3), one week later in the third treatment session (T4), and one week later at post-intervention (T5), and four weeks later at follow-up assessment (T6) | |
Secondary | Change in approach behaviour (Time and Distance) | Approach behaviour will be measured by three situational Behavioural Approach Tests (BAT) for feared and avoided objects or situations. The test consists of a number of increasingly difficult steps in which children are asked to approach a phobic object or situation, but are told they can stop the test at any time they wish to do so. During the BAT, individuals are asked to provide "subjective unit of disturbance scale" (SUDS 0-100 ratio scale) ratings immediately after encountering the phobic animal or situation. | Time Frame: At pre-intervention assessment (T1), four weeks later at post-intervention assessment (T5) and four weeks later at follow-up assessment (T6) | |
Secondary | Change in self-efficacy (Academic, Social and Emotional) | Self-efficacy will be measured by the Self Efficacy Questionnaire for Children (SEQ-C). This questionnaire contains 24 questions regarding academic, social and emotional self-efficacy. Items are rated on a 5-point interval scale from 'not at all' (1) to 'very well' (5). The SEQ-C is proven to be a valid instrument with sufficient reliability. | Time Frame: At pre-intervention assessment (T1), four weeks later at post-intervention assessment (T5) and four weeks later at follow-up assessment (T6) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04594525 -
Maternal Telemental Health Interventions in Response to Covid-19*
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT03233113 -
The Effects of Safety Seeking Behaviors During Exposure Therapy for Adults With Spider Phobia
|
N/A | |
Completed |
NCT04504773 -
Using Immersive Virtual Reality to Treat Pediatric Anxiety
|
N/A | |
Completed |
NCT05300061 -
Values Interventions for Increasing Engagement With What is Feared in Individuals With Specific Phobias
|
N/A | |
Completed |
NCT03208400 -
Virtual Reality Exposure in Spider Phobia
|
N/A | |
Completed |
NCT03688360 -
Facing Fears In-session or Out-session?
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT03764644 -
Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
|
N/A | |
Terminated |
NCT01979263 -
Attention Bias Modification Treatment for Anxious Youth
|
N/A | |
Not yet recruiting |
NCT02972112 -
Ultrashort Cognitive Behavioral Intervention for Tokophobia- A Prospective Randomized Single Blinded Controlled Trial
|
N/A | |
Completed |
NCT02554838 -
How to Act on the Mobility Restriction Linked to Senior's Phobia of Falling
|
N/A | |
Completed |
NCT01491880 -
Treatment Study for Rural Latino Youth With Anxiety
|
Phase 1/Phase 2 | |
Completed |
NCT01947647 -
Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders
|
N/A | |
Recruiting |
NCT04563390 -
Effectiveness of a Projection-based Augmented Reality Exposure System in Treating Cockroach Phobia.
|
N/A | |
Completed |
NCT05284435 -
Internet-Based, Parent-Led Cognitive-Behavioral Therapy for Anxiety in Youth With ASD
|
N/A | |
Completed |
NCT03105024 -
Self-efficacy Enhancement and Exposure Therapy
|
N/A | |
Completed |
NCT01923896 -
D-cycloserine and Treatment of Feeding Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03917550 -
RECOVERY: A Transdiagnostic Intervention for Anxiety and Depression
|
N/A | |
Completed |
NCT02756507 -
Transdiagnostic REBT Prevention Program for Adolescents
|
N/A |